News | October 23, 2006

Catheter Improves 89-Year-Old Woman's Calcified Aortic Valve

CoreValve announced that its patented ReValving System, consisting of a 18F delivery catheter, was used to percutaneously implant its proprietary porcine pericardial-tissue bioprosthesis over the severely calcified aortic heart valve of an 89-year-old woman. In contrast to long post-surgical recuperation times, this PAVR patient was discharged from the ICU to the general ward on the morning after her ReValving procedure and was fully mobile and awaiting discharge from the hospital.

The successful procedure was performed at Erasmus University Medical Center, Rotterdam, The Netherlands, by Professor Patrick W. Serruys and Dr. Peter DeJaegere, globally recognized interventional cardiologists who have been leading investigators in clinical trials of numerous cutting-edge technologies.


Additional Content

News | Heart Valve Technology

Oct. 29, 2026 — Abbott has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its ...

Home November 05, 2026
Home
News | Heart Valve Technology

Oct. 21, 2026 — Edwards Lifesciences Corp. recently announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 23, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Following transcatheter aortic valve implantation (TAVI), disturbances in the heart’s electrical ...

Home September 25, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have received a $3.6 million, four-year ...

Home September 24, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Subscribe Now